Search results
Results from the WOW.Com Content Network
Novartis also initiated a program to assist patients who could not afford its version of the drug, concurrent with its product launch. [175] When examination of Novartis' patent application began in 2005, it came under immediate attack from oppositions initiated by generic companies that were already selling Gleevec in India and by advocacy ...
Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the patent application.
Novartis made use of the EMR to obtain orders against some generic manufacturers who had already launched Gleevec in India. [82] [83] When examination of Novartis' patent application began in 2005, it came under immediate attack from oppositions initiated by generic companies that were already selling Gleevec in India and by advocacy groups ...
The Swiss competition commission (COMCO) has initiated an investigation against Novartis AG (NYSE: NVS) over the alleged unlawful patent use to reduce competitive pressure. COMCO conducted an ...
Swiss drug major Novartis AG (NYSE: NVS) plans to petition the U.S. Supreme Court to uphold the validity of the Gilenya (fingolimod) dosing regimen patent. The decision comes as the U.S. Court of ...
Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it accidentally overpaid by nearly $210 ...
Novartis had filed a patent for Glivec in 1997. [30] An exclusive marketing right was also granted for Novartis in 2003 and the application were approved in 2005 . [ 30 ] In 2013, the Supreme Court of India upheld the rejection of the patent application of Glivec by Novartis , [ 31 ] ending the 10-years battle between the proprietary drug ...
For premium support please call: 800-290-4726 more ways to reach us